Kaklamani Speaks to a Shifting HER2+ Breast Cancer Paradigm
In Partnership With:
Dr. Kaklamani discusses current treatment sequencing approaches in HER2-positive breast cancer and the benefits and challenges of moving effective treatments in earlier lines of therapy.
Welcome to a very special edition of Onclive On Air™! I’m your host today, Jessica Hergert.
OncLive On Air™ is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.
In today’s episode, sponsored by Daiichi-Sankyo, we had the pleasure of speaking with Virginia Kaklamani, MD, a professor of medicine in the Division of Hematology and Oncology at UT Health San Antonio and the leader of the Breast Cancer Program at UT Health San Antonio MD Anderson Cancer Center, to discuss the importance of strategic treatment sequencing in HER2-positive breast cancer.
In our exclusive interview, Kaklamani discussed current treatment sequencing approaches in HER2-positive breast cancer and the benefits and challenges of moving effective treatments in earlier lines of therapy.
